Effects of micronized fenofibrate on insulin resistance in patients with metabolic syndrome

International Journal of Clinical Pharmacology and Therapeutics

Volumn 42, Issue 4, 2004, Pages 212-217

  Wysocki, J ^a   Belowski, D ^a   Kalina, M ^a   Kochanski, L ^a   Okopien, B ^a   Kalina, Z ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Insulin resistance; Metabolic syndrome; Micronized fenofibrate

Indexed keywords

FENOFIBRATE; HIGH DENSITY LIPOPROTEIN; INSULIN; INSULIN ANTIBODY; NEUTRAL INSULIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DYSLIPIDEMIA; FEMALE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; LIPID ANALYSIS; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SELECTION; PILOT STUDY; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 1842788708     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP42212     Document Type: Article

References (25)

1. Avogaro A, Beltramelle P, Martin R et al 1995 Insulin action and glucose metabolism are improved by gemfibrozil treatment in hypertriglyceridemic patients. Atherosclerosis 113: 117-123
2. Balfour JA, McTavish D, Heel RC 1990 Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic place in dyslipidemia. Drugs 40: 260-290
3. Berthezene F 1996 Noninsulin-dependent diabetes mellitus and reverse cholesterol transport. Atherosclerosis 124 (Suppl): S39-S42
4. Bjorntop P 1990 "Portal" adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis 10: 493-496
5. Blane GF 1989 Review of European clinical experience with fenofibrate. Cardiology 76 (Suppl): 1-13
6. Bonora E, Moghetti P, Zancanaro C et al 1989 Estimates of in vivo insulin action in man: comparison of insulin tolerance tests with euglycemic and hyperglycemic glucose clump studies. J Clin Endocrinol Metab 68: 374-378
7. Carmena R, Ascaso JF 1996 Influence of insulin resistance on lipid metabolism. Czynniki Ryzyka (in English 14: 4-10
8. Cavallero E, Piolot A, Jacotot B 1995 Postprandial lipoprotein clearance in type 2 diabetes: fenofibrate effects. Diab Metab 21: 118-120
9. Fruchart JC 2000 (PPAR) activation: enhancing the protective power of HDL-C. Clinician 18: 19-23
10. Gelding SV, Robinson S, Lowe S et al 1994 Validation of the low-dose short insulin tolerance test for evaluation of insulin sensitivity. Clin Endocrinol 40: 611-615
11. Grulet H, Durlach V, Hecart AC et al 1993 Study of the rate of early glucose disappearance following insulin action: insulin sensitivity index. Diabetes Res Clin Pract 20: 201-207
12. Haring HU, Schleicher E, Renner R, Mehner H 1983 Effect of fenofibrate on the lipid level in diabetics. Münch Med Wochenschr 125: 751-753
13. Hirst S, Phillips DIW, Vines SK et al 1993 Reproducibility of the short insulin tolerance test. Diab Med 10: 839-842
14. Idzior-Walus B, Sieradzki J, Roztworowski W et al 2000 Effects of comicronized fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X. Eur J Clin Invest 30: 871-878
15. Matthews DR, Hosker JP, Rudensky AS et al 1985 Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419
16. Phillips DIW, Clark PM, Hales CN, Osmond C 1993 Understanding oral glucose tolerance: comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion. Diab Med 11: 286-292
17. Ratzmann KP, Zegenhagen R 1994 Fenofibrate treatment of diabetic patients with hyperlipidemia. Impact on glycemic control. Münch Med Wochenschr 136: 41-46
18. Reaven G 2001 Insulin resistance, dyslipidemia, and coronary heart disease in syndrome X. In: Schwartz CJ, Born GVR (eds) Occlusive Arterial Disease. The Interfaces Among Dyslipidemias, Hypertension and Diabetes. Schattauer, Stuttgart, pp 227-236
19. Schonfeld G 1994 Recent concepts of lipoprotein pathophysiology. Atherosclerosis 110 (Suppl): S3-S9
20. Shepherd J 1994 The fibrates in clinical practice: focus on micronized fenofibrate. Atherosclerosis 110 (Suppl): S55-S63
21. Smud R, Sermukslis B 1987 Bezafibrate and fenofibrate in type II diabetics with hyperlipoproteinemia. Curr Med Res Opin 10: 612-624
22. Sommariva D, Branchi A, Tirrito M et al 1987 Differential effects of benfluorex and two fibrate derivatives on serum lipoprotein patterns in hypertriglyceridemic type 2 diabetic patients. Curr Ther Res 40: 859-870
23. Steiner G 1994 Hyperinsulinemia and hypertriglyceridemia. J Intern Med 236 (Suppl 736): 23-26
24. Taton J 2001 Diabetologia. Wydawnictwo Lekarskie PZWL, Warszawa
25. Report of a WHO Consultation 1999 Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. WHO, Geneva